Reducing delays in time-critical medications for Parkinson’s disease: a multifaceted, multiprofessional quality improvement project.

Reducing delays in time-critical medications for Parkinson’s disease: a multifaceted, multiprofessional quality improvement project.

Publication date: Jan 30, 2026

When people with Parkinson’s disease (PD) are admitted to hospital, control of their symptoms can deteriorate, often due to delayed or incorrect medication administration. The aim of this project was to improve the administration of PD medicines for hospital in-patients in our trust. Specifically, we aimed to administer 95% of PD medicines within 30 minutes of the prescribed time and to eliminate delays of >60 minutes for PD medications. To achieve these aims, we developed a multifaceted quality improvement project, led by a multidisciplinary team, that ran over a period of 2 years. The outcome measure in this project was the time delay between the time a given PD medicine was scheduled to be administered and the time at which it was recorded as having been administered by nursing staff. The data were divided into 3 phases: a 6-month baseline phase (March 2022 to September 2022), a 24-month project phase (September 2022 to September 2024) and a 6-month sustain phase (September 2024 to March 2025). Statistical process control (SPC) charts were used to monitor medicine delays over time. Plan-do-study-act methodology was adopted within this project and a variety of interventions were employed throughout the project. The project demonstrated a significant reduction in delays in medicines administration for patients with PD. The success of our project came from the cultivation of multiprofessional ‘ownership’ of the problem, in combination with an appreciation of the patient’s lived experience, through visualisation of how poor symptom control can impact on a person’s ability to move. Whilst it is not possible to comment on the long-term sustainability of the project, we were encouraged that the changes were maintained throughout the 6-month sustain phase for both medicine administration targets.

Open Access PDF

Concepts Keywords
Disease Antiparkinson Agents
Month Antiparkinson Agents
Parkinson Geriatrics
Sustainability Healthcare quality improvement
Humans
Medication safety
Parkinson Disease
Quality Improvement
Quality improvement
Time Factors
Time-to-Treatment
Time-to-Treatment

Semantics

Type Source Name
disease MESH Parkinson’s disease
drug DRUGBANK Ranitidine
drug DRUGBANK Etoperidone
disease MESH Plan
drug DRUGBANK Spinosad
disease MESH neuroleptic malignant syndrome
drug DRUGBANK Coenzyme M
disease MESH hos
disease MESH NHS
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH dysphagia
disease MESH Death
drug DRUGBANK Amantadine
drug DRUGBANK Apomorphine
drug DRUGBANK Biperiden
drug DRUGBANK Cabergoline
drug DRUGBANK Entacapone
drug DRUGBANK Opicapone
drug DRUGBANK Pergolide
drug DRUGBANK Rasagiline
drug DRUGBANK Riluzole
drug DRUGBANK Ropinirole
drug DRUGBANK Rotigotine
drug DRUGBANK Tolcapone
drug DRUGBANK Gold
disease MESH included
disease MESH emergency
drug DRUGBANK Trestolone
drug DRUGBANK Levodopa
drug DRUGBANK Huperzine B
pathway KEGG Parkinson disease

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *